June 19, 2020 / 12:19 PM / a month ago

BRIEF-Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation For OV101

June 19 (Reuters) - Ovid Therapeutics Inc:

* OVID THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR OV101 FOR THE TREATMENT OF ANGELMAN SYNDROME

* OVID THERAPEUTICS - MAY BE ELIGIBLE TO RECEIVE PRIORITY REVIEW VOUCHER FROM FDA, PROVIDING VALUE AS CO WORKS ON COMPLETNG OF NEPTUNE TRIAL

* OVID THERAPEUTICS INC - TOPLINE RESULTS EXPECTED IN Q4 OF 2020 FROM PHASE 3 NEPTUNE TRIAL IN ANGELMAN SYNDROME Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below